Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1293492.RA6HgD3-vLg8GpmjyifpEJ-MOA_QcmZY6cs_fpkgwCCeM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1293492.RA6HgD3-vLg8GpmjyifpEJ-MOA_QcmZY6cs_fpkgwCCeM130_assertion type Assertion NP1293492.RA6HgD3-vLg8GpmjyifpEJ-MOA_QcmZY6cs_fpkgwCCeM130_head.
- NP1293492.RA6HgD3-vLg8GpmjyifpEJ-MOA_QcmZY6cs_fpkgwCCeM130_assertion description "[Furthermore, we demonstrate that inhibition of MEK1/2 with trametinib increased sensitivity of ALL cells and primary samples to chemotherapy in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293492.RA6HgD3-vLg8GpmjyifpEJ-MOA_QcmZY6cs_fpkgwCCeM130_provenance.
- NP1293492.RA6HgD3-vLg8GpmjyifpEJ-MOA_QcmZY6cs_fpkgwCCeM130_assertion evidence source_evidence_literature NP1293492.RA6HgD3-vLg8GpmjyifpEJ-MOA_QcmZY6cs_fpkgwCCeM130_provenance.
- NP1293492.RA6HgD3-vLg8GpmjyifpEJ-MOA_QcmZY6cs_fpkgwCCeM130_assertion SIO_000772 26324703 NP1293492.RA6HgD3-vLg8GpmjyifpEJ-MOA_QcmZY6cs_fpkgwCCeM130_provenance.
- NP1293492.RA6HgD3-vLg8GpmjyifpEJ-MOA_QcmZY6cs_fpkgwCCeM130_assertion wasDerivedFrom befree-2016 NP1293492.RA6HgD3-vLg8GpmjyifpEJ-MOA_QcmZY6cs_fpkgwCCeM130_provenance.
- NP1293492.RA6HgD3-vLg8GpmjyifpEJ-MOA_QcmZY6cs_fpkgwCCeM130_assertion wasGeneratedBy ECO_0000203 NP1293492.RA6HgD3-vLg8GpmjyifpEJ-MOA_QcmZY6cs_fpkgwCCeM130_provenance.